Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies
Sumit Kar(Revolution Medicines (United States)), Mallika Singh(Revolution Medicines (United States)), Minal Barve(Mary Crowley Cancer Research Center), Lo Lai(Georgia State University), Matthew Holderfield(Revolution Medicines (United States)), Elsa Quintana(Revolution Medicines (United States)), David S. Hong(The University of Texas MD Anderson Cancer Center), Ignacio Garrido‐Laguna(University of Utah), Wan-Ying Hsieh(Cornell University), Wungki Park(University of Miami), Aparna Hegde(University of Colorado Cancer Center), Alexander I. Spira(Virginia Cancer Specialists), Brett Garrick(Revolution Medicines (United States)), Brian M. Wolpin(Harvard University), Anirban Maitra(NYU Langone Health), Harika Gundlapalli(Revolution Medicines (United States)), Vidya Devanathadesikan Seshadri(Revolution Medicines (United States)), David Sommerhalder(Texas Oncology), Salman R. Punekar(NYU Langone Health), Mark P. Labrecque(Revolution Medicines (United States)), Cristina Blaj(Revolution Medicines (United States)), Ida Aronchik(Revolution Medicines (United States)), Andrew J. Aguirre(Broad Institute), W. Clay Gustafson(Revolution Medicines (United States)), Yevgeniy Gindin(Revolution Medicines (United States)), Ethan Ahler(Revolution Medicines (United States)), Lingyan Jiang(Revolution Medicines (United States)), Yongxian Zhuang(Mayo Clinic), Meredith Pelster(Mary Crowley Cancer Research Center), Jingjing Jiang(Shanghai Jiao Tong University), Jim Evans(Revolution Medicines (United States)), Jacqueline Smith(Revolution Medicines (United States)), Kevin K. Lin(Revolution Medicines (United States)), Alexander Starodub(Dana-Farber Cancer Institute), Shurui Cai(The Ohio State University), Marie Ménard(University of California, San Francisco), Sean Bredeson(Revolution Medicines (United States)), Zeena Salman(Revolution Medicines (United States))
Cited by 9
Related Papers
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
|Cancer Cell|2017|2.1k